Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.60 |
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30462513 | 0.90 | MTNR1A (0.57) | MTNR1ADAOP2RX7PARP1SLC22A12 | |
| SCHEMBL14578714 | 0.88 | MTNR1A (0.56) | MTNR1ADAOP2RX7PARP1SLC22A12 | |
| SCHEMBL16195505 | 0.85 | MTNR1A (0.55) | MTNR1ADAOP2RX7PARP1SLC22A12 | |
| SCHEMBL8134945 | 0.82 | MTNR1A (0.56) | MTNR1ADAOP2RX7PARP1SLC22A12 | |
| SCHEMBL8135642 | 0.82 | MTNR1A (0.56) | MTNR1ADAOP2RX7PARP1SLC22A12 | |
| SCHEMBL8827650 | 0.82 | MTNR1A (0.56) | MTNR1ADAOP2RX7PARP1SLC22A12 | |
| SCHEMBL7771626 | 0.82 | MTNR1A (0.60) | MTNR1ADAOP2RX7PARP1SLC22A12 | |
| SCHEMBL9039466 | 0.81 | MTNR1A (0.55) | MTNR1ADAOP2RX7PARP1SLC22A12 | |
| SCHEMBL2127227 | 0.80 | MTNR1A (0.62) | MTNR1ADAOP2RX7PARP1SLC22A12 | |
| SCHEMBL327116 | 0.78 | MTNR1A (0.56) | MTNR1ADAOP2RX7PARP1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505753-B2 | Inhibitors of D-amino acid oxidase | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150218156-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-08-06 | — | — | US | disclosed |
| WO-2014025993-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-02-13 | — | — | WO | disclosed |
| US-7179581-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-7179581-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| EP-1660427-A4 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1660427-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016862-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-02-24 | — | — | WO | disclosed |
| EP-0676398-B1 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | disclosed |
| CN-1060173-C | Heterocyclic compound with activity against diabetes and preparation and application of same | MITSUTAKA CO LTD (JP) | 2001-01-03 | — | — | CN | disclosed |
| US-6117893-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-1022274-A1 | Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5977365-A | HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5962470-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| CN-1118781-A | Heterocyclic compound with activity against diabetes and preparation and application of same | MITSUTAKA CO LTD (JP) | 1996-03-20 | — | — | CN | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218156-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, GRIN2A | MTNR1A 482/4885DAO 2/4885P2RX7 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.